Prostate cancer is the most common malignancy in the incarcerated population. Screening, staging, and treatment recommendations have changed significantly. Screening for prostate cancer remains controversial. The revised NCCN screening guidelines will be reviewed. The many therapy options dictate good communication between provider and patient, weighing risks and benefits of therapy while considering comorbidities, patient expectations, and life expectancy. On-site prostate cancer surveillance is desirable with prompt recognition of PSA relapse. Radiation oncology centers should use hypofractionated treatment plans. Screening, staging, and treatment recommendations have changed significantly.

Learning Objectives:

• Review the benefits of cancer screening
• Describe the role of genomic testing in prostate cancer
• Evaluate the costs of prostate cancer treatment modalities

Level: Advanced